MEDP

Medpace Holdings

Stock NASDAQ – Stock Market Prices, News & Analysis

Medpace Holdings Inc specializes in providing clinical research services for drug development, primarily in the biopharmaceutical and medical device sectors.

$ 521.84
0.64 %

Medpace Holdings

$ 521.84
0.64 %
MEDP

Medpace Holdings Inc specializes in providing clinical research services for drug development, primarily in the biopharmaceutical and medical device sectors.

Price history of Medpace Holdings
Price history of Medpace Holdings

Performance & Momentum

6 Months 0.12 %
1 Year 76.00 %
3 Years 166.90 %
5 Years 190.07 %

Strategic Analysis

Medpace Holdings • 2026

Medpace Holdings Inc positions itself as a key player in clinical research services, specializing in supporting the development of biopharmaceutical drugs and medical devices. Its model is based on in-depth expertise and an integrated offering optimized to accelerate the market introduction of therapeutic innovations.

Strengths
  • Recognized positioning in a highly regulated sector with high barriers to entry
  • Solid growth supported by the dynamics of pharmaceutical and medical development
  • Diversified portfolio between biotechnology and medical devices, limiting sectoral risks
Weaknesses
  • Sensitivity to investment cycles and the pace of clinical trials
  • Exposure to complex regulations that may impact timelines and costs
Momentum

Medpace's momentum shows an overall favorable trend supported by an improving valuation in the medium term, despite a recent correction. This reflects market confidence in its ability to benefit from the rise of medical innovations, provided it maintains operational control in a competitive environment.

Similar stocks to Medpace Holdings

Was this page helpful?

Your feedback helps us improve our research.

Take control
of your investments

Track your portfolios, analyze your performance and receive personalized insights to invest with strategy.

  • Real-time multi-portfolio tracking
  • AI analysis of your positions
  • Counter your cognitive biases
Anantys Invest on iPhone